Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous lidocaine plus ropivacaine infiltration for recovery after laparoscopic colorectal cancer surgery
2025-523207-29-00Phase 4Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in colorectal cancer (CRC) comparing Intravenous lidocaine + ropivacaine infiltration with Ropivacaine infiltration control (2 arms). Primary endpoint: Postoperative recovery at 24 hours. Planned start Apr 2026; status: authorised.
02
Drugs
lidocaineropivacaine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2025-523207-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523207-29-00.